Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL) (Aurora)

8 de julho de 2026 atualizado por: Lu Huaiwu, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

A Prospective, Open-label, Randomized, Controlled, Non-inferiority Phase II Study Comparing HAL-PDT With Deferred Surgery Versus Immediate Surgery in Subjects With High-grade Squamous Intraepithelial Lesions (HSIL)

High-grade squamous intraepithelial lesions (HSIL), encompassing cervical intraepithelial neoplasia grade 2 (CIN2) with p16 positivity and grade 3 (CIN3), are precancerous conditions that require effective intervention. This Phase II study aims to comprehensively evaluate the efficacy, safety, and impact on quality of life of hexaminolevulinate photodynamic therapy (HAL-PDT) with deferred surgery compared to immediate surgical treatment in subjects with HSIL.

This is a prospective, open-label, randomized, controlled, non-inferiority trial. A total of 230 subjects are planned to be enrolled, with 115 subjects allocated to each treatment group (HAL-PDT with Deferred Surgery or Immediate Surgery ).

The primary endpoint is the pathological regression rate at 12 months, defined as histological findings of normal tissue or low-grade squamous intraepithelial lesions (LSIL) via colposcopy-directed biopsy. Key secondary endpoints include Human Papillomavirus (HPV) clearance rates at 6 and 12 months, pathological regression rate at 6 months, quality of life assessed by the EORTC QLQ-CX24 questionnaire, safety profiles (incidence, severity, and duration of AEs and SAEs, as well as their relationship to the study treatments), and the proportion of subjects developing cervical cancer within 12 months.

Visão geral do estudo

Descrição detalhada

High-grade squamous intraepithelial lesions (HSIL), encompassing cervical intraepithelial neoplasia grade 2 (CIN2) with p16 positivity and grade 3 (CIN3), are well-established precursors to invasive cervical cancer. Immediate excisional procedures such as loop electrosurgical excision procedure (LEEP) or cold knife conization remain the standard of care; however, they are associated with significant long-term morbidities, including cervical stenosis, cervical incompetence, and adverse obstetric outcomes in women of childbearing age. Hexaminolevulinate photodynamic therapy (HAL-PDT) is a non-invasive, tissue-preserving modality that offers a potential alternative.

This Phase II trial is designed to test the hypothesis that HAL-PDT (HAL-PDT Q2W×6 ) with deferred surgery achieves a 12-month pathological regression rate non-inferior to that of immediate surgery, while providing a favorable safety and quality-of-life profile.

A total of 230 subjects are planned for enrollment, with 115 allocated to each treatment arm. The primary efficacy analysis will be performed on both the Intention-to-Treat (ITT) and Per-Protocol (PP) populations to test the non-inferiority margin, which is pre-specified based on clinically acceptable thresholds. Safety analyses will be conducted on the Safety Set (SS).

Tipo de estudo

Intervencional

Inscrição (Estimado)

230

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Fujian
      • Fuzhou, Fujian, China, 350001
        • Fujian Medical University Union Hospital
        • Contato:
          • Ethics Committee Administrator
          • Número de telefone: 0591-83357896
          • E-mail: fjxhe_irb@163.com
        • Investigador principal:
          • Dezhao Chen, MD, PhD
      • Fuzhou, Fujian, China, 350005
        • The First Affiliated Hospital of Fujian Medical University
        • Contato:
          • Ethics Committee Administrator
          • Número de telefone: 0591-87982001
          • E-mail: fdyy_irb@163.com
        • Investigador principal:
          • Lihong Chen, MD, PhD
      • Xiamen, Fujian, China, 361001
        • Xiamen Maternity and Child Healthcare Hospital
        • Contato:
          • Ethics Committee Administrator
          • Número de telefone: 0592-2662920
          • E-mail: xmfyllwyh@163.com
        • Investigador principal:
          • Qing Li, MD, PHD
      • Xiamen, Fujian, China, 361003
        • he First Affiliated Hospital of Xiamen University
        • Contato:
          • Jiajie Lin
          • Número de telefone: +86-0592-2137569
          • E-mail: xdfyec@163.com
        • Investigador principal:
          • Qionghua Chen, MD, PHD
    • Guangdong
      • Foshan, Guangdong, China, 528000
        • The First People's Hospital of Foshan
        • Contato:
        • Investigador principal:
          • Lijiang Xu, MD, PHD
      • Foshan, Guangdong, China, 528300
        • Foshan Shunde Maternal and Child Health Hospital
        • Contato:
        • Investigador principal:
          • Jinzhi Huang, MD, PHD
      • Guangzhou, Guangdong, China, 510280
        • Zhujiang Hospital, Southern Medical University
        • Contato:
          • Ethics Office Administrator
          • Número de telefone: +86-020-62783372
          • E-mail: zjyygcp@163.com
        • Investigador principal:
          • Xuefeng Wang, MD, PhD
      • Guangzhou, Guangdong, China, 510010
        • Guangdong Women and Children Hospital
        • Contato:
        • Investigador principal:
          • Xiaoli Sun, MD, PHD
      • Guangzhou, Guangdong, China, 510095
        • The Affiliated Cancer Hospital of Guangzhou Medical University
        • Contato:
        • Investigador principal:
          • Bin Wen, MD, PhD
      • Guangzhou, Guangdong, China, 510120
        • Guangdong ProvincialHospital of Chinese Medicine
        • Contato:
          • Administrator Ethics Committee
          • Número de telefone: 020-81887233-35943
          • E-mail: Ilbgs@gzucm.edu.cn
        • Investigador principal:
          • Jing Xiao, MD, PhD
      • Guangzhou, Guangdong, China, 510180
        • Guangzhou First People's Hospital (The Second Affiliated Hospital of South China University of Technology)
        • Contato:
          • Ethics Committee Administrator
          • Número de telefone: 020-81045412
          • E-mail: MEC_GZSY@126.com
        • Investigador principal:
          • Yan Kuang, MD, PhD
      • Guangzhou, Guangdong, China, 510317
        • Guangdong Second Provincial GeneralHospital (Guangdong Provincial Emergency Hospital)
        • Contato:
          • Administrator Clinical Research Office
          • Número de telefone: +86-20-89168338
          • E-mail: gdech_irb@163.com
        • Investigador principal:
          • Xiafei Fu, MD, PhD
      • Guangzhou, Guangdong, China, 510405
        • The First AffiliatedHospital, Guangzhou University ofTraditional Chinese Medicine
        • Contato:
          • Ethics Committee Administrator
          • Número de telefone: +86-20-36588667
          • E-mail: gztcmlunli@163.com
        • Investigador principal:
          • Sijin Li, MD, PhD
      • Guangzhou, Guangdong, China, 510623
        • Guangzhou Women and Children's Medical Center (The Affiliated Women and Children's Medical Center of Guangzhou Medical University)
        • Contato:
          • Ethics Committee Administrator
          • Número de telefone: 020-81886332
          • E-mail: gzwc_irb@163.com
        • Investigador principal:
          • Kun Shi, MD, PhD
      • Guangzhou, Guangdong, China, 511400
        • Panyu Central Hospital Affiliated to Guangzhou Medical University
        • Contato:
          • Ethics Committee Administrator
          • Número de telefone: 020-34858888
          • E-mail: pyzxylunli@163.com
        • Investigador principal:
          • Xiang Yang, MD, PhD
      • Shenzhen, Guangdong, China, 518036
        • Peking University Shenzhen Hospital
        • Contato:
          • Ethics Committee Administrator
          • Número de telefone: 0755-83923333
          • E-mail: pkuszh_irb@163.com
        • Investigador principal:
          • Zhihong Liu, MD, PhD
      • Shenzhen, Guangdong, China, 518031
        • Shenzhen Maternity and Child Health Hospital
        • Contato:
        • Investigador principal:
          • Ping Jin, MD, PHD
      • Zhongshan, Guangdong, China, 510080
        • The First Affiliated Hospital, Sun Yat-sen University
        • Contato:
        • Investigador principal:
          • Mian He, MD, PHD
        • Investigador principal:
          • Junxiu Liu, MD, PHD
    • Guangxi
      • Nanning, Guangxi, China, 530021
        • The First Affiliated Hospital of Guangxi Medical University
        • Contato:
        • Investigador principal:
          • Jiangtao Fan, MD, PhD
      • Nanning, Guangxi, China, 530000
        • Guangxi Zhuang Autonomous Region Maternal and Child Health Hospital
        • Contato:
        • Investigador principal:
          • Chunqiu Xiong, MD, PHD
    • Guangzhou
      • Dongguan, Guangzhou, China, 523000
        • Dongguan Maternal and Child Health Care Hosptial
        • Contato:
        • Investigador principal:
          • Ping Zhou, MD, PHD
    • Henan
      • Zhengzhou, Henan, China, 450052
        • The First Affiliated Hospital of Zhengzhou University
        • Contato:
          • Ethics Committee Administrator
          • Número de telefone: 0371-66278510
          • E-mail: zdyyllwy@163.com
        • Investigador principal:
          • Liping Han, MD, PhD
    • Jiangsu
      • Nanjing, Jiangsu, China, 210029
        • The First Affiliated Hospital with Nanjing Medical University (Jiangsu Provincial People's Hospital)
        • Contato:
          • Ethics Committee Administrator
          • Número de telefone: 025-68136360
          • E-mail: jsphkj@163.com
        • Investigador principal:
          • Xiaoling Ma, MD, PhD
    • Jinlin
      • Changchun, Jinlin, China
        • The First Hospital of Jilin University
        • Contato:
        • Investigador principal:
          • Songling Zhang, MD, PHD
    • Liaoning
      • Shenyang, Liaoning, China, 110016
        • The General Hospital of Northern Theater Command of the Chinese People's Liberation Army
        • Contato:
          • Ethics Committee Administrator
          • Número de telefone: 024-28851114
          • E-mail: btzzyy_irb@163.com
        • Investigador principal:
          • Lipeng Pei, MD, PhD
    • Shanxi
      • Taiyuan, Shanxi, China, 030000
        • Shanxi Provincial People's Hospital
        • Contato:
        • Investigador principal:
          • Yuping Suo, MD, PHD
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • The West China Second University Hospital of Sichuan University
        • Contato:
        • Investigador principal:
          • Yuedong He, MD, PHD
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310022
        • Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
        • Contato:
          • Ethics Committee Administrator
          • Número de telefone: 0571-88125287
          • E-mail: zjszlyy_irb@163.com
        • Investigador principal:
          • Yichen Wang, MD, PhD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Filho
  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  • Voluntarily participate in this clinical study, fully understand the study content, procedures, and potential adverse reactions, and be able to sign the written informed consent form.
  • Able to complete the study in accordance with the study protocol.
  • Subject age ≥18 years.
  • Presence of High-Grade Squamous Intraepithelial Lesion (HSIL) (CIN2 P16 positive/CIN3), specifically: HSIL with histopathological diagnosis of grade II/III (CIN2 P16 positive/CIN3) within 3 months prior to the first treatment.
  • Adequate colposcopy, including: (a) Complete visibility of the cervical transformation zone, including the squamocolumnar junction; (b) Complete visibility of lesion margins.
  • The investigator determines that non-surgical treatment is acceptable for the participant.
  • The investigator determines that the cervical size is suitable for placement of the HAL-PDT device.
  • Meets the following conditions: Women of childbearing potential (WOCBP) must have a negative serum pregnancy test result prior to the start of treatment. No plan for pregnancy during the study period; no sexual activity or use of effective and reliable contraception from the end of the last menstrual period to the start of the study, and agreement to use condoms for barrier contraception during the study period. WOCBP is defined as a female who has experienced menarche, has not undergone hysterectomy or bilateral oophorectomy, and has not reached natural menopause (i.e., no menstruation at all for the past 24 consecutive months).

Exclusion Criteria:

  • Cervical adenocarcinoma in situ or other glandular lesions, invasive cervical cancer, or suspected malignant lesions.
  • CIN2 with P16 negative.
  • Lesions extending to the vaginal wall, cervical canal, or vaginal fornix, or lesions located on the vulva.
  • Prior physical or surgical treatment to the cervix resulting in incomplete cervical structure (e.g., cold knife conization), or receipt of physical or surgical therapy for CIN2 or CIN3 after the current histopathological diagnosis.
  • The first study treatment day falls within 7 half-lives of the last antiviral medication.
  • Severe pelvic inflammatory disease, severe cervicitis, or other severe gynecological infectious diseases found on colposcopic or clinical examination.
  • Investigator judges that vaginal bleeding during treatment may affect treatment outcomes.
  • Receipt of any inactivated vaccine within 2 weeks prior to the first treatment, or any live vaccine within 4 weeks prior to the first treatment.
  • Previous severe cardiovascular, cerebrovascular, neurological, psychiatric, endocrine, or hematopoietic disease that has not been cured; known severely compromised immune function, or need for long-term use of corticosteroids or immunosuppressants; history of malignancy within 5 years.
  • History of clinically significant immunosuppression or confirmed autoimmune disease; or primary immunodeficiency.
  • Known or newly identified active sexually transmitted diseases (STDs), including but not limited to HIV, syphilis, genital herpes, unless adequately treated and tested negative before study treatment.
  • Presence of a cardiac pacemaker.
  • Suspected or known porphyria, or known allergy to the study drug, its chemically similar compounds, or photosensitizers.
  • Allergy to silicone.
  • Pregnant or breastfeeding women.
  • Delivery or miscarriage within 6 weeks prior to enrollment.
  • Participation in any other clinical trial within 30 days prior to study treatment.
  • Poor compliance or judged by the investigator to be unsuitable for participation in this clinical study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Hexaminolevulinate Photodynamic Therapy (HAL-PDT) with Deferred Surgery
Subjects receive Hexaminolevulinate Photodynamic Therapy (HAL-PDT) once every 2 weeks (Q2W) for a total of 6 treatment sessions. At 6 months after the first treatment, participants undergo colposcopy-directed cervical biopsy and HPV testing to assess treatment response. Those who achieve pathological remission (normal or LSIL) enter follow-up without surgery. Those who do not achieve remission (persistent HSIL or disease progression) receive standard surgical treatment (LEEP or CKC) within 4 weeks of the 6-month assessment.
HAL-PDT is a drug-device combination product. The drug is hexaminolevulinate hydrochloride (HAL) 5% ointment. The device is a single-use cervical light delivery device (CL7) with integrated red LEDs. The ointment is applied into the device cup, placed against the cervix for 5 hours of drug absorption, then automatically delivers 125 J/cm² photodynamic therapy for 4 hours and 36 minutes. Total in-situ time is 11-24 hours. Patients remove the device themselves. Treatment regimen: one session every 2 weeks for a total of 6 sessions (Q2W × 6).
Comparador Ativo: Immediate Surgery
Participants with histologically confirmed HSIL (CIN2 P16 positive/CIN3) receive standard surgical treatment (LEEP or CKC) per routine clinical practice. Follow-up assessments include HPV testing and colposcopy-directed cervical biopsy at 6 months and 12 months post-surgery to evaluate pathological remission and HPV clearance rates. Safety monitoring is conducted from signing of informed consent through the end of study.
Subjects undergo immediate surgical excision of the cervical lesion via either Loop Electrosurgical Excision Procedure (LEEP) or Cold Knife Conization (CKC), as determined by the investigator based on the subject's individual lesion characteristics, size, and clinical presentation, following standard institutional surgical protocols.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Histopathological regression rate at 12 months
Prazo: 12 months after the first treatment
Proportion of participants with pathological remission on colposcopy-directed cervical biopsy at 12 months after the first treatment. Pathological remission is defined as histopathological finding of normal tissue or low-grade squamous intraepithelial lesion (LSIL)
12 months after the first treatment

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Pathological remission rate at 6 months
Prazo: 6 months after the first treatment
Proportion of participants with pathological remission on colposcopy-directed cervical biopsy at 6 months after the first treatment. Pathological remission is defined as histopathological finding of normal tissue or low-grade squamous intraepithelial lesion (LSIL).
6 months after the first treatment
HPV baseline clearance rate at 12 months
Prazo: 12 months after the first treatment
Proportion of participants with clearance of baseline high-risk HPV subtypes at 12 months after the first treatment. HPV clearance is defined as undetectable of the same high-risk HPV subtype(s) that were present at baseline.
12 months after the first treatment
Incidence of cervical cancer at 12 months
Prazo: 12 months after the first treatment
Proportion of participants with histologically confirmed cervical cancer (any stage) diagnosed within 12 months after the first treatment.
12 months after the first treatment
Human Papillomavirus (HPV) baseline clearance rate at 6 months
Prazo: 6 months after the first treatment
Proportion of participants with clearance of baseline high-risk Human Papillomavirus (HPV) subtypes at 6 months after the first treatment. HPV clearance is defined as undetectable of the same high-risk HPV subtype(s) that were present at baseline.
6 months after the first treatment
Quality of life assessed by EORTC QLQ-CX24
Prazo: 12 months after the first treatment
Quality of life assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Cervical Cancer Module (EORTC QLQ-CX24). Scores for each domain are linearly transformed to a 0-100 scale. For global health status and functional domains, a higher score indicates a better outcome (better quality of life/function). For symptom scales, a higher score indicates a worse outcome (more severe symptoms).
12 months after the first treatment
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
Prazo: From informed consent through 12 months after the first treatment
Incidence, type, severity (mild, moderate, severe), duration, and relatedness to photodynamic therapy and/or surgical treatment of adverse events (AEs) and serious adverse events (SAEs) occurring from signing of informed consent through the end of study follow-up.
From informed consent through 12 months after the first treatment

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de julho de 2026

Conclusão Primária (Estimado)

16 de junho de 2029

Conclusão do estudo (Estimado)

16 de junho de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

21 de junho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

21 de junho de 2026

Primeira postagem (Real)

25 de junho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

9 de julho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

8 de julho de 2026

Última verificação

1 de julho de 2026

Mais Informações

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever